

**STATE OF FLORIDA
DIVISION OF ADMINISTRATIVE HEARINGS**

AIDS HEALTHCARE FOUNDATION, INC.,
and RECIPIENT ONE,

Petitioners,

vs.

DOAH Case No. _____

FLORIDA DEPARTMENT OF HEALTH,

Respondent.

_____ /

**PETITION CHALLENGING AGENCY STATEMENTS AS
UNPROMULGATED RULES AND REQUEST FOR EXPEDITED HEARING**

Petitioners, AIDS Healthcare Foundation, Inc. (“AHF”) and Recipient One (“Petitioners”), petition the Division of Administrative Hearings for an administrative determination that statements by the Florida Department of Health (“Respondent” or “Department”) constitute invalid, unenforceable, and unpromulgated rules. The Department has issued letters to multiple patients who are recipients of medication and health care premium insurance support under the grant program provided by the United States Health and Human Services Ryan White Part B AIDS Drug Assistance Program (“ADAP”) and administered through the Department, indicating that these patients will no longer receive these life-saving services as of March 1, 2026. The Department has issued statements of general applicability without engaging in the mandatory rulemaking process required under Florida’s Administrative Procedure Act. Petitioners seek relief pursuant to sections 120.56(1) and 120.56(4), Florida Statutes. Support for this Petition follows:

I. THE PARTIES

1. The agency affected by this proceeding is the Department of Health, and its principal place of business is 4052 Bald Cypress Way, Tallahassee, Florida 32399, telephone number (850)245-4444.

2. AHF is a Foreign Not-For-Profit Corporation authorized to do business in Florida. AHF's principal address is 700 SE Third Ave., Fourth Floor, Fort Lauderdale, Florida 33316.

3. Recipient One is a Florida resident currently receiving medication and insurance premium assistance benefits from ADAP. Recipient One's address is confidential.

4. For the purposes of this proceeding, AHF's and Recipient One's contact information is that of the undersigned counsel.

5. AHF is the largest non-profit HIV/AIDS organization in the world, providing health care services to more than 2.7 million individuals. AHF provides services to patients eligible for and receiving ADAP services in Florida, through contracts throughout the state. AHF holds a total of 16 contracts with the Department to provide clinical services to patients at risk for HIV infection and patients diagnosed with HIV or AIDS in Florida; four of these are Part B contracts.

II. FACTUAL AND PROCEDURAL HISTORY

6. The Ryan White HIV/AIDS Program ("RWHAP") is housed within the Federal Health Resources & Services Administration ("HRSA"), an agency within the U.S. Department of Health and Human Services ("HHS"). Since 1990, the program

has provided grants to states to pay for medical and support services for low-income people living with HIV. More than 50% of people diagnosed with HIV receive assistance from RWHAP each year.

7. Without proper care and treatment, AIDS is a terminal disease. Every year, thousands of Americans die from HIV/AIDS. With proper care and treatment, including access to expensive antiretroviral medications and regular health care, AIDS is a chronic but manageable disease.

8. ADAP, provided through RWHAP Part B, provides FDA-approved medications, including antiretroviral treatments, medications for opportunistic infections, and drugs for hepatitis B/C, to individuals living with HIV/AIDS. These medications turn HIV/AIDS from a fatal disease into a manageable condition. Removing or interrupting any part of that system can lead to viral rebound, drug resistance, hospitalization, and death.

9. Currently, one of the medications available under the ADAP formulary is Biktarvy, a widely recommended full HIV/AIDS treatment regimen in one pill. Biktarvy has become the gold standard first-line therapy because it combines a high barrier to resistance, good tolerability, and the simplicity of one pill per day, which supports patient medication adherence.

10. Another widely used medication currently available to all patients under ADAP is Descovy. Descovy is not a full HIV/AIDS regimen like Biktarvy, and must be used in combination with other antiretroviral agents for treating HIV/AIDS.

However, Descovy replaced an older HIV/AIDS medication due to its lower risk of kidney toxicity and bone density.

11. Removing an individual's access to Biktarvy/Descovy can result in serious consequences, such as high risk of poor adherence and viral rebound, reduced clinical ability to provide optimal care, psychological harm to patients, and broader public health risks due to potential increases in HIV transmission. Restricting drug options also forces clinicians to prescribe older or less optimal medications for reasons not driven by clinical need.

12. ADAP also provides health insurance premium support (allowing eligible patients to purchase health insurance) to eligible individuals living with HIV. This is not a peripheral benefit, but the primary mechanism through which many people with HIV/AIDS obtain uninterrupted access to antiretroviral therapy and the medical care necessary to stay alive. Modern HIV treatment requires continuous access to a complex and expensive combination of antiretroviral medications, laboratory monitoring, and physician care. ADAP's health insurance premium support allows patients to purchase that access by paying insurance premiums for individuals living with HIV/AIDS who otherwise would not be able to afford this life-saving care and treatment. HIV/AIDS infection also correlates and has comorbidities with a number of other physical and mental health issues, and insurance premium support helps to provide whole-person care and coverage for all conditions affecting these patients.

13. Restricting health insurance premium assistance and medication access will lead to treatment interruptions, medical crisis, and preventable deaths for many

individuals currently receiving such assistance. These outcomes directly contradict the purpose of ADAP and the RWHAP.

14. In fiscal year 2024, RWHAP awarded \$84,895,726.00 to Florida for the administration of ADAP; Florida’s total fiscal year 2024 RWHAP Part B funding was \$134,661.497.00.

15. The Department is the state agency tasked with conducting communicable disease prevention and control programs for the prevention and control of HIV and AIDS under chapters 381 and 384. § 381.003(1)(b), Fla. Stat. The Department receives RWHAP Part B grant funding as part of this core public health mission that it has been tasked to administer by the Florida Legislature.

16. Florida is tasked, under the Public Health Service Act,¹ with defining “low-income” individuals to be eligible for ADAP benefits.

17. In 2007, the Department promulgated rules relating to ADAP eligibility in Florida Administrative Code Chapter 64D-4. Since October 27, 2008, the Department has defined “low income” to be adjusted gross household income² “at or below 400 percent of the Federal Poverty Level.” R. 64D-4.002(6), Fla. Admin. Code (eff. 10-12-22).

18. The same rules define “HIV/AIDS Patient Care Programs” to include the “Ryan White Part B AIDS Drug Assistance Program, a program that provides medications to uninsured or underinsured individuals living with HIV/AIDS disease.”

¹ 42 U.S.C. § 300ff-26(b).

² The word “adjusted” appears before gross household income in the currently-effective version of the rule, but did not appear in the October 2008 version.

It indicates that such services are provided through the distribution of medications directly to eligible clients or by the purchase of health insurance that includes coverage for HIV/AIDS medications.

19. To be eligible for ADAP, the premium assistance program, and the HIV/AIDS patient care program service, an individual must (1) have a positive HIV test, (2) be living in Florida, (3) not be receiving the same services or be eligible to receive the same services through another program, (4) **must have low income** as defined by rule, (5) must submit a completed application and cooperate with the eligibility process and abide by the program requirements, and (6) must have their eligibility confirmed every 366 days (or sooner if their income or other factors change).

R. 64D-4.003, Fla. Admin. Code (eff. 10-12-22).

III. THE DEPARTMENT'S UNPROMULGATED RULES

20. In January 2026, the Department began issuing at least two versions of letters to patients currently benefitting from the Department's administration of ADAP. One version of the letter (**Exhibit A**) indicates that the patient will no longer receive premium insurance support and medication services through ADAP as of February 28, 2026, and the second (**Exhibit B**) indicates that the patient remains eligible for direct medication services through ADAP, but notifies them that if they are currently taking Biktarvy, they must contact their health care provider to receive a prescription for a clinically equivalent medication because Biktarvy will no longer be offered. Both letters note that the Department will only provide funding to patients if their income is at or below 130% of the Federal Poverty Level.

Additionally, the Department's webpage notes that ADAP will only cover costs of HIV medications directly for individuals at or below 130% of the Federal Poverty Level (**Exhibit C**).³

21. Recipient One is an individual currently receiving the benefits provided through ADAP for health insurance premium and medication coverage. Recipient One will lose this coverage based upon the Department's unadopted rules.

22. The National Alliance of State and Territorial AIDS Directors ("NASTAD") estimates that more than 16,000 patients in Florida will lose ADAP coverage because of this change in Department policy. AHF provides services through ADAP to a number of these patients who will lose their ability to pay health insurance premiums, impacting all aspects of their physical and mental wellbeing, and a number of patients who will no longer be able to access life-saving medications.

23. The letters issued to ADAP recipients in Florida, as well as the Department's public-facing messaging, including that of its webpage and of the State Surgeon General, describe eligibility restrictions that differ from those set forth in the governing rules, and remove life-saving medications from the Florida ADAP formulary (attached as **Exhibit D**). The various rules governing the Department's administration of the ADAP program have not been modified through the mandatory rulemaking process.

24. The Department has declared that individuals who are currently eligible for ADAP services between 130% and 400% of the Federal Poverty Level will not be

³ <https://www.floridahealth.gov/individual-family-health/injury-prevention-wellness/hiv-aids/hiv-aids-management/> (Last visited January 25, 2026).

eligible for any ADAP medication services, that individuals receiving insurance premium assistance services will no longer be eligible for those services beginning on March 1, 2026, and even those individuals remaining eligible for the Department's ADAP benefits will be subject to reduced and restricted access to ADAP approved medications. However, the Department has not modified the existing rule to redefine "low income."

25. Further, the Department has removed Biktarvy from the ADAP formulary and has indicated that Descovey will now only be available to patients with renal insufficiency. However, Department has not made these changes to the HIV/AIDS patient care program through the mandatory rulemaking process.

26. An unpromulgated rule is any "statement of general applicability that implements, interprets, or prescribes law or policy or describes the organization, procedure, or practice requirements of an agency" and has not been properly promulgated in conformance with section 120.54, Florida Statutes. *Dep't of Revenue v. Vanjara Enters., Inc.*, 675 So. 2d 252, 255 (Fla. 5th DCA 1996) (internal citations omitted). This includes any such statement which "imposes any requirement" on a regulated party beyond what is promulgated. *Id.*; see also *State Bd. of Admin. v. Huberty*, 46 So. 3d 1144, 1147 (Fla. 1st DCA 2010). While an agency statement that merely reiterates a law or restates what is readily apparent from the text of a law may not be considered a rule, "[a]n agency statement or policy is a rule if its effect requires compliance, creates certain rights while adversely affecting others, or otherwise has the direct and consistent effect of law." *Dep't of Health v. Leafly*

Holdings, Inc., 369 So. 3d 333 (quoting *Jenkins v. State*, 855 So.2d 1219, 1225 (Fla. 1st DCA 2003)); *St. Francis Hosp., Inc. v. Dep't of Health and Rehab. Servs.*, 553 So.2d 1351, 1354 (1st DCA. 1989).

27. The focus in determining whether an agency statement is a rule within the meaning of section 120.52(16), Florida Statutes, is on the effect of the statement rather than the agency's characterization of it. *Dep't of Rev. v. Vanjaria Enters., Inc.*, 675 So. 2d 252, 255 (Fla. 5th DCA 1996); *Balsam v. Dep't of HRS*, 452 So. 2d 976, 977 (Fla. 1st DCA 1984); *Amos v. Dep't of HRS*, 444 So. 2d 43, 46-47 (Fla. 1st DCA 1983); *State Dep't of Admin. v. Harvey*, 356 So. 2d 323, 325 (Fla. 1st DCA 1977).

28. A statement is not generally applicable if it is applied solely on a case-by-case basis. *Agency for Health Care Admin. v. Custom Mobility, Inc.*, 995 So. 2d 984, 986 (Fla. 1st DCA 2008). However, a statement need not apply to every party in a given field to meet this requirement. *Dep't of Highway Safety & Motor Vehicles v. Schluter*, 705 So. 2d 81, 83 (Fla. 1st DCA 1997).

29. Policies that apply only to specific subgroups have been determined to meet the definition of a rule and, therefore, be generally applicable. *Harvey*, 356 So. 2d at 323 (statement applied only to career-service state employees, not state employees as a whole); *Schluter*, 705 So. 2d at 83 (applied to all policemen under investigation, not police as a whole); *Williams v. Dep't of Highway Safety & Motor Vehicles*, DOAH Case No. 16-6127RU (Fla. DOAH Mar. 3, 2017) (applied to all vehicles coming into Florida from a foreign country, not vehicles as a whole). Such is

the case when a policy applies “uniformly to a class of persons or activities over which the [agency] exercises authority.” *Williams*, DOAH Case No. 16-6127RU, ¶ 41.

30. Rulemaking is not a matter of agency discretion. § 120.54(1)(a), Fla. Stat. Each agency statement that meets the statutory definition of a rule must be adopted through rulemaking procedures as soon as feasible and practicable. § 120.54(1)(a), Fla. Stat.

31. A rule is defined in the Florida Administrative Procedure Act as:

(16) “Rule” means each agency statement of general applicability that implements, interprets, or prescribes law or policy or describes the procedure or practice requirements of an agency and includes any form which imposes any requirement or solicits any information not specifically required by statute or by an existing rule. The term also includes the amendment or repeal of a rule. The term does not include:

(a) Internal management memoranda which do not affect either the private interests of any person or any plan or procedure important to the public and which have no application outside the agency issuing the memorandum.

(b) Legal memoranda or opinions issued to an agency by the Attorney General or agency legal opinions prior to their use in connection with an agency action.

(c) The preparation or modification of:

1. Agency budgets.
2. Statements, memoranda, or instructions to state agencies issued by the Chief Financial Officer or Comptroller as chief fiscal officer of the state and relating or pertaining to claims for payment submitted by state agencies to the Chief Financial Officer or Comptroller.
3. Contractual provisions reached as a result of collective bargaining.
4. Memoranda issued by the Executive Office of the Governor relating to information resources management.

§ 120.52(16), Fla. Stat. (2025).

32. The policy announced by the Department through its statements, webpage, and letters to ADAP recipients constitutes statements of general applicability that change existing eligibility requirements under Florida Administrative Code Chapter 64D-4. It does not meet the definition of any exceptions to what constitutes a rule in Florida law.

33. The Department has failed to promulgate this new policy as a rule, and it therefore violates section 120.54(1)(a) because it has not been adopted by rule.

III. PETITIONERS' SUBSTANTIAL INTERESTS ARE AFFECTED

34. Under Florida law, “[a]ny person substantially affected by an agency statement that is an unadopted rule may seek an administrative determination that the statement violates s. 120.54(1)(a).” § 120.56(4)(a), Fla. Stat. The fact that a party will be regulated by a rule at issue in an administrative proceeding is “alone sufficient to establish that their substantial interests will be affected.” *Reiff v. Ne. Fla. State Hosp.*, 710 So. 2d 1030, 1032 (Fla. 1st DCA 1998) (quoting *Coalition of Mental Health Professions v. Dep’t of Prof’l Reg.*, 546 So. 2d 27 (Fla. 1st DCA 1989)).

35. AHF administers RWHAP Part B benefits to eligible HIV/AIDS patients in Florida through both contracts with the Department and other municipalities. The Department’s modified policy substantially affects AHF’s ability to comply with the requirements of these agreements, including providing services to patients eligible to receive them under current Florida law. Thus, AHF’s interests are substantially affected by the Department’s new and modified policy.

36. Recipient One is a beneficiary of RWHAP Part B/ADAP. The Department's unadopted policy substantially affects Recipient One in that he will no longer be able to obtain medications approved or health insurance premium support based on the stated policy that will be in effect March 1, 2026.

IV. DISPUTED ISSUES OF MATERIAL FACT

37. Disputed issues of material fact include, but are not limited to:

- a. Whether the Department's statements modifying the maximum percentage of Federal Poverty Levels for ADAP medication and premium assistance eligibility constitute an unadopted rule;
- b. Whether the Department's intended action to remove ADAP medication and premium assistance coverage for currently-eligible patients, and modify and further restrict medication access for eligible patients, is pursuant to an unadopted rule; and
- c. Whether the Department should be prohibited from relying on the unadopted rule.
- d. Whether the Department's statements modifying the ADAP formulary constitute an unadopted rule;
- e. Whether the Department's intended action to remove Biktarvy and modify Descovy coverage for currently-eligible patients is pursuant to an unadopted rule; and
- f. Whether the Department should be prohibited from relying on the unadopted rule.

V. CONCISE STATEMENT OF ULTIMATE FACTS ALLEGED

38. The Department's modification of patient eligibility for ADAP benefits from 400% of the Federal Poverty Level to 130% of the Federal Poverty Level constitutes an unadopted rule in violation of section 120.54(1).

39. The Department's removal of patient eligibility for ADAP insurance premium assistance constitutes an unadopted rule in violation of section 120.54(1).

40. The Department's modification of the ADAP drug formulary to remove Biktarvy and restrict Descovy constitutes an unadopted rule in violation of section 120.54(1).

41. The Department's removal of patient eligibility for certain drugs under the HIV/AIDS patient care program constitutes an unadopted rule in violation of section 120.54(1).

VI. RULES OR STATUTES REQUIRING MODIFICATION OF AGENCY ACTION

42. Specific statutes and rules requiring modification of the Department's actions include, but are not limited to, sections 120.52, 120.54, 120.56, 381.0011, and 381.003, Florida Statutes, and Chapter 64D-4, Florida Administrative Code.

VII. RESERVATION OF RIGHT TO AMEND

43. AHF has pending public records requests with the Department that remain unfulfilled. Therefore, AHF reserves the right to amend this petition as additional facts become known through the review of documents received in response to public records requests and discovery conducted in this case.

VIII. REQUEST FOR EXPEDITED HEARING

44. Because approximately 16,000 individuals in Florida stand to lose their life-saving ADAP benefits and will be left without viable alternatives to live healthy lives and prevent additional spread of HIV as of March 1, 2026, the standard timeframe of 30 days for the hearing to commence and 30 days to render a Final Order provided in section 120.56 is direly inadequate.

45. The Department has brought this emergency to patients on itself, and AHF respectfully requests an expedited scheduling order for discovery, final hearing, and Final Order be considered. AHF recommends five days for discovery, 14 days for a hearing, and 14 days for a Final Order.

IX. ENTITLEMENT TO ATTORNEY'S FEES

46. Section 120.595(4) provides that, if the Administrative Law Judge determines that any statement by the Department alleged herein constitutes an unadopted rule, or that the Department must immediately discontinue reliance on the statement, an "...order shall be entered against the agency for reasonable costs and reasonable attorney's fees...." No exception applies. As a result, should any Petitioner prevail in this matter, Petitioners respectfully request the award of reasonable costs and reasonable attorney's fees.

X. RELIEF REQUESTED

WHEREFORE, based upon the foregoing, AHF respectfully requests that:

- a. A formal administrative hearing pursuant to sections 120.569 and 120.57(1) be held in an expedited manner;

- b. A Final Order be entered determining that the Department's policy set forth in the letters to patients and in public-facing statements constitutes an unadopted rule and violates section 120.54(1)(a); and ordering the Department to immediately discontinue all reliance upon the unadopted rule or any substantially similar statement;
- c. An award of reasonable costs and reasonable attorney's fees be entered; and
- d. Grant any other relief as may be deemed just, appropriate, or necessary.

Respectfully submitted,

/s/Louise Wilhite-St Laurent
LOUISE WILHITE-ST LAURENT
LStLaurent@panzamaurer.com
Florida Bar No.: 91244
SAMANTHA EVANS SALTZBURG
SEvans@panzamaurer.com
Florida Bar No.: 124088
Panza, Maurer & Maynard, P.A.
201 East Park Avenue, Suite 200A
Tallahassee, FL 32301
Tel: (850) 681-0980

ATTORNEYS FOR PETITIONERS


CERTIFICATE OF SERVICE

I HEREBY CERTIFY that on January 27, 2026, the foregoing has been e-filed with the Division of Administrative Hearings and a copy furnished to the following via e-mail:

Alysson Bradley
Interim General Counsel
Florida Department of Health
4052 Bald Cypress Way, Bin A-02
Tallahassee, Florida 32399
Alysson.Bradley@flhealth.gov

/s/Louise Wilhite-St Laurent
LOUISE WILHITE-ST LAURENT

EXHIBIT A
TO UNPROMULGATED RULE
CHALLENGE



You are receiving the following information as you have been identified as a client that is currently receiving premium insurance support and medication services through the U.S. Health and Human Services grant program known as the Ryan White Part B Drug Assistance Program (ADAP).

Due to the increase in the cost of HIV/AIDS medication and health insurance premiums, eligibility criteria for current Ryan White Part B ADAP clients will change.

The federal funding limitation requires an adjustment to the services provided by the ADAP Patient Care Program and reassessment of clients that will be served by the Ryan White Part B ADAP. Effective March 1, 2026, ADAP Patient Care services will no longer be offering the ADAP Premium Plus Insurance Program. ADAP Patient Care services will be limited to providing medication services through the Ryan White Part B ADAP.

Records indicate that, as of March 1, 2026, you will no longer be eligible to receive health insurance and direct medication services through the Ryan White Part B ADAP. Based on our records, your insurance coverage will end on February 28, 2026.

Eligibility for receiving direct medication assistance through the Ryan White Part B ADAP program will be prioritized based on the Federal Poverty Level of up to 130%. For any questions regarding the direct medication services eligibility, please contact Prime Therapeutics, LLC., at 1-833-604-0925.

Clients who are no longer serviced by the Ryan White Part B ADAP can seek alternative services through the following resources:

- **NASTAD Pharmaceutical Assistance Resources:**
<https://nastad.org/resources/pharmaceutical-company-patient-assistance-programs-and-cost-sharing-assistance-programs>
- **Florida Medicaid:** <https://myaccess.myflfamilies.com/Public/login>
- **Medicare:** <https://www.cms.gov/medicare/enrollment-renewal/original-part-a-b>

Please contact the ADAP Help Desk at 844-381-2327 with any questions.





EXHIBIT B
TO UNPROMULGATED RULE
CHALLENGE

January 8, 2026


You are receiving the following information as you have been identified as a client that is currently receiving direct medication services through the U.S. Health and Human Services grant program known as the Ryan White Part B Drug Assistance Program (ADAP).

Due to the increase in the cost of HIV/AIDS medication and health insurance premiums, eligibility criteria for current ADAP clients will change.

Under current federal funding limitations, clients that are serviced by the Ryan White Part B ADAP will be prioritized based on the Federal Poverty Level up to 130% effective March 1, 2026. In addition, Biktarvy will no longer be available on the ADAP formulary as a medication option for Ryan White Part B ADAP clients receiving direct medication assistance, however, clinically equivalent medications will still be available.

Records indicate you are eligible to continue receiving direct medication services through the Ryan White Part B ADAP. Additionally, if you are currently taking Biktarvy, please contact your health care provider to receive a prescription for a clinically equivalent medication.

Please contact the ADAP Help Desk at 844-381-2327 with any questions regarding these changes and to coordinate any medication changes that will be required.



Vision:
To be the **Healthiest State** in the Nation



Accredited Health Department
Public Health Accreditation Board



EXHIBIT C
TO UNPROMULGATED RULE
CHALLENGE

County Health Departments

Select Language

[Home](#) / [Individual & Family Health](#) / [Prevention & Wellness](#) / [HIV/AIDS](#) / [AIDS Drug Assistance Program](#)

AIDS DRUG ASSISTANCE PROGRAM

UPDATES TO ADAP

Due to rising health care insurance premiums nationwide and lack of additional Ryan White Grant funding, adjustments have been made to ensure resources the greatest number of individuals within our funding constraints.

The Department remains committed to delivering services through this vital program and will instead cover the costs of HIV medications directly for individuals at or below 130% of the **Federal Poverty Level**. The Department will also cover costs during a two-month transition period to ensure clients have adequate time to connect to services if they are impacted by these changes. These adjustments will prevent a shortfall of more than \$120 million for Florida.

We encourage those in need to connect with available community resources to help with connection to care:

PATIENT ASSISTANCE PROGRAMS

- **National Alliance of State and Territorial AIDS Directors (NASTAD) Pharmaceutical Companies Patient Assistance Programs and Cost-Sharing Assistance Programs**
- **Patient Advocate Foundation Co-Pay Relief**
- **HarborPath Non-Profit Assistance**

COMMUNITY, STATE, AND FEDERAL RESOURCES

- **Florida Association of Community Health Centers**
- **Florida Non-Profit HIV/AIDS Organizations**
- **Florida Medicaid**
- **Medicare (individuals age 65 and older)**
- **Medication Discounts**

- [Medicine Assistance Tool](#)
- [U.S. Department of Veteran Affairs](#)

The AIDS Drug Assistance Program (ADAP) is a statewide, federally-funded prescription medication program for low-income people living with HIV. This program provides access to medications to eligible clients either directly or by purchase of health insurance that includes coverage for HIV medications.

STEP 1: Eligibility and Verification

STEP 2: Enrollment

STEP 3: Getting Prescriptions Filled

SAME DAY Program

ADAP Insurance

Quarterly Reports

Program Assistance

ADAP Medication ADAP Formulary Workgroup

Prevention & Wellness



- Chronic Disease Prevention & Management
- Eating Healthy Seafood
- Food Access
- Healthy Aging, Healthy Brain



HIV/AIDS



AIDS Drug Assistance Program

- Community Programs
- Florida Comprehensive Planning Network
- Housing Opportunities for Persons With AIDS
- Linkage to Care
- Planning and Program Administration
- Prevention



- Human Trafficking
- Injury Prevention
- Preventing Mosquito and Tick Bites
- Sexual Violence
- Substance Use & Overdose Prevention
- Suicide Prevention
- Tobacco Free Florida



AIDS DRUG ASSISTANCE PROGRAM

844-381-2327

Monday-Friday

8 a.m. – 5 p.m.



Led by the State Surgeon General, the mission of the Florida Department of Health is to protect, promote, and improve the health of all people in Florida through integrated state, county, and community efforts.

ABOUT FLORIDA HEALTH



[Leadership](#)



[Agency Organization](#)



[Careers with Florida Health](#)



[Contact Us](#)

RESOURCES



[Public Records Requests](#)



[Public Meeting Notices](#)



[Public Notices](#)



[Boards, Councils, and Committees](#)

[ACCESSIBILITY](#)

[ACCREDITATION](#)

[DISCLAIMER](#)

[ELECTRONIC
COMMUNICATION](#)

[PRIVACY POLICY](#)

[SITE MAP](#)



EXHIBIT D
TO UNPROMULGATED RULE
CHALLENGE

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|---|----------------------------|--------------------------------------|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Brand Name (listed for Antiretroviral drugs only) | Therapeutic Classification | Pharmacologic Classification |
| abacavir | Ziagen | Antiretroviral | NRTI |
| abacavir / lamivudine | Epzicom | Antiretroviral | NRTI combo |
| abacavir / dolutegravir / lamivudine | Triumeq | Antiretroviral | INSTI/NRTI combo |
| atazanavir | Reyataz | Antiretroviral | PI |
| atazanavir/cobicistat | Evotaz | Antiretroviral | PI/PK Enhancer |
| bictegravir / emtricitabine / tenofovir alafenamide | Biktarvy | Antiretroviral | INSTI/NRTI combo |
| cabotegravir | Vocabria | Antiretroviral | INSTI |
| cabotegravir / rilpivirine | Cabenuva | Antiretroviral | INSTI/NNRTI combo |
| cobicistat | Tybost | Antiretroviral | PK Enhancer |
| darunavir | Prezista | Antiretroviral | PI |
| darunavir / cobicistat | Prezcobix | Antiretroviral | PI/PK Enhancer |
| darunavir / cobicistat / emtricitabine / tenofovir alafenamide | Symtuza | Antiretroviral | PI/NRTI combo |
| dolutegravir | Tivicay | Antiretroviral | INSTI |
| dolutegravir / lamivudine | Dovato | Antiretroviral | INSTI/NRTI combo |
| dolutegravir / rilpivirine | Juluca | Antiretroviral | INSTI/NNRTI combo |
| doravirine | Pifeltro | Antiretroviral | NNRTI |
| doravirine / lamivudine / tenofovir disoproxil fumarate | Delstrigo | Antiretroviral | NNRTI/NRTI combo |
| efavirenz | Sustiva | Antiretroviral | NNRTI |
| efavirenz / emtricitabine / tenofovir disoproxil fumarate | N/A | Antiretroviral | NNRTI/NRTI combo |
| efavirenz / lamivudine / tenofovir disoproxil fumarate | Symfi, SymfiLo | Antiretroviral | NNRTI/NRTI combo |
| elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide | Genvoya | Antiretroviral | INSTI/NRTI combo |
| elvitegravir / cobicistat / emtricitabine /tenofovir disoproxil fumarate | Stribild | Antiretroviral | INSTI/NRTI combo |
| emtricitabine | Emtriva | Antiretroviral | NRTI |
| emtricitabine / tenofovir alafenamide | Descovy | Antiretroviral | NRTI combo |
| emtricitabine / tenofovir disoproxil fumarate | Truvada | Antiretroviral | NRTI combo |
| enfuvirtide | Fuzeon | Antiretroviral | Fusion inhibitor |
| etravirine | Intelence | Antiretroviral | NNRTI |
| fostemsavir | Rukobia | Antiretroviral | Gp-120 directed attachment inhibitor |
| ibalizumab-uiyk injection ^{PA} | Trogarzo ^{PA} | Antiretroviral | CD4 post-attachment HIV-1 inhibitor |
| lamivudine | Epivir | Antiretroviral | NRTI |
| lamivudine / zidovudine | Combivir | Antiretroviral | NRTI combo |
| lenacapavir | Sunlenca | Antiretroviral | Capsid inhibitor |
| lopinavir / ritonavir | Kaletra | Antiretroviral | PI/PK Enhancer |
| maraviroc | Selzentry | Antiretroviral | CCR5 antagonist |
| nevirapine, nevirapine XR | Viramune, Viramune XR | Antiretroviral | NNRTI |
| raltegravir, raltegravir HD | Isentress, Isentress HD | Antiretroviral | INSTI |
| rilpivirine | Edurant | Antiretroviral | NNRTI |
| rilpivirine / emtricitabine/ tenofovir disoproxil fumarate | Complera | Antiretroviral | NNRTI/NRTI combo |
| rilpivirine / emtricitabine / tenofovir alafenamide | Odefsey | Antiretroviral | NNRTI/NRTI combo |
| ritonavir | Norvir | Antiretroviral | PK Enhancer |
| tenofovir alafenamide | Vemlidy | Antiretroviral | NRTI |
| tenofovir disoproxil fumarate | Viread | Antiretroviral | NRTI |

INSTI = Integrase Strand Transfer Inhibitor, NNRTI = Non-Nucleoside Reverse Transcriptase Inhibitor, NRTI = Nucleoside/Nucleotide Reverse Transcriptase Inhibitor, PK= Pharmokinetic, PI = Protease Inhibitor

| tenofovir disoproxil fumarate / lamivudine | Cimduo, Temixys | Antiretroviral | NRTI combo |
|---|--|---|--|
| zidovudine | Retrovir | Antiretroviral | NRTI |
| <div>Florida AIDS Drug Assistance Program (ADAP) Formulary</div> <div>September 2024</div> <div>****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.****</div> <div>CS indicates controlled substance. PA indicates prior authorization required.</div> | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| acetaminophen | Analgesic | Non-salicylate analgesic | capsule, tablet, oral liquid, rectal suppository |
| acetaminophen/hydrocodone ^{CS} | Analgesic | Nonsalicylate/opioid | capsule, tablet, oral liquid |
| acetaminophen/oxycodone ^{CS} | Analgesic | Nonsalicylate/opioid | tablet, oral liquid |
| acetazolamide | Antiglaucoma | Carbonic anhydrase inhibitor | capsule, tablet |
| acyclovir | Anti-infective | Antiviral | capsule, tablet, oral liquid, topical |
| albuterol | Respiratory | Beta-2 Agonist | inhaler, nebulizer solution, tablet, oral liquid |
| albuterol HFA | Respiratory | Beta-2 Agonist | inhaler |
| albuterol/ipratropium | Respiratory | Anticholinergic + Beta-2 Agonist, oral inhaled | inhaler, nebulizer solution |
| alendronate | Osteoporosis | Bisphosphonate | tablet, oral liquid |
| alirocumab | Cardiovascular, antihyperlipidemic | PCSK9 inhibitor | injection |
| allopurinol | Antigout | Xanthine oxidase inhibitor | tablet |
| amitriptyline | Central nervous system, antidepressant | Tricyclic antidepressant (TCA) | tablet |
| amlodipine | Cardiovascular | Calcium channel blocker | tablet, oral liquid |
| amlodipine/atorvastatin | Cardiovascular | Calcium channel blocker/HMG-CoA reductase inhibitor | tablet |
| amlodipine/benazepril | Cardiovascular | Calcium channel blocker/ACE inhibitor | capsule |
| amlodipine/olmesartan | Cardiovascular, antihypertensive | Calcium channel blocker/angiotensin II receptor blocker | tablet |
| amlodipine/valsartan | Cardiovascular, antihypertensive | Calcium channel blocker/angiotensin II receptor blocker | tablet |
| ammonium lactate | Dermatologic | Humectant | topical |
| amoxicillin | Anti-infective | Beta-lactam antibiotic | capsule, tablet, oral liquid |
| amoxicillin/clavulanate | Anti-infective | Beta-lactam antibiotic/beta-lactamase inhibitor | tablet, oral liquid |
| amphetamine/dextroamphetamine ^{CS} | Central nervous system | ADHD agent, stimulant | tablet, capsule |
| apixaban | Blood formation and coagulation | Anticoagulant | tablet |
| aripiprazole | Central nervous system | Antipsychotic, atypical | tablet, injection |
| aspirin | Analgesic | Salicylate | caplet, tablet, rectal suppository |
| atenolol | Cardiovascular | Beta-blocker | tablet |
| atenolol/chlorthalidone | Cardiovascular | Beta-blocker/thiazide-like diuretic | tablet |
| atomoxetine | Central nervous system | ADHD agent, non-stimulant | capsule |
| atorvastatin | Cardiovascular, antihyperlipidemic | HMG-CoA reductase inhibitor | tablet, oral liquid |
| atovaquone | Anti-infective | Amebicide | oral liquid |
| azelastine | Respiratory | Antihistamine | nasal spray, eye drops |
| azelastine/fluticasone | Respiratory | Antihistamine/corticosteroid, intranasal | nasal spray |
| azithromycin | Anti-infective | Macrolide antibiotic | tablet, oral liquid, eye drops |
| baclofen | Central nervous system | Muscle relaxant | tablet, oral liquid |
| baloxavir | Anti-infective | Anti-influenza antiviral | tablet, oral liquid |
| beclomethasone | Respiratory | Corticosteroid | nasal spray, inhaler |
| bempedoic acid | Cardiovascular, antihyperlipidemic | ACL inhibitor | tablet |
| benazepril | Cardiovascular | Angiotensin converting enzyme (ACE) inhibitor | tablet |
| benazepril/hydrochlorothiazide | Cardiovascular | ACE inhibitor/ thiazide diuretic | tablet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|--|---|---|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| benzoyl peroxide | Dermatologic | Antibiotic + keratolytic | topical |
| benzoyl peroxide/clindamycin | Dermatologic | Anti-acne retinoid | topical |
| benztropine | Central nervous system | Anticholinergic | tablet |
| betamethasone dipropionate | Dermatologic | Corticosteroid | topical |
| betamethasone valerate | Dermatologic | Corticosteroid | topical |
| betamethasone/clotrimazole | Dermatologic | Corticosteroid, antifungal | topical |
| bisacodyl | Gastrointestinal | Laxative, stimulant | tablet, rectal suppository |
| bismuth subcitrate potassium/metronidazole/tetracycline | Gastrointestinal | Helicobacter pylori agents | tablets and capsules (therapy kit) |
| brexpiprazole | Central nervous system | Antipsychotic, atypical | tablet |
| brimonidine | Antiglaucoma | Alpha-2 agonist | eye drops, eye gel |
| brimonidine/timolol | Antiglaucoma | Alpha agonist/beta blocker | eye drops |
| budesonide | Respiratory | Corticosteroid | inhaler, nasal spray |
| budesonide/formoterol | Respiratory | Corticosteroid + Long acting Beta-2 Agonist, oral inhaled | inhaler |
| budesonide/glycopyrrolate/formoterol | Respiratory | Corticosteroid/anticholinergic/long-acting Beta-2 agonist | inhaler |
| buprenorphine/naloxone ^{CS} | Substance abuse | Opiate agonist/antagonist | tablet, oral film |
| buprenorphine ^{CS} | Substance abuse | Opiate agonist/antagonist | tablet, oral film, patch |
| bupropion | Central nervous system | Antidepressant-miscellaneous, aminoketone | tablet |
| buspirone | Central nervous system | Anxiolytic | tablet |
| calcium carbonate | Vitamin | Vitamin | tablet, oral liquid |
| calcium with vitamin D | Vitamin | Vitamin | tablet |
| canagliflozin | Antidiabetic | Sodium-glucose co-transporter 2 (SGLT2) inhibitor | tablet |
| canagliflozin/metformin | Antidiabetic | SGLT2 inhibitor/biguanide | tablet |
| capsaicin | Dermatologic | Analgesic | topical |
| carbamazepine | Central nervous system | Anti-manic, anti-seizure | tablet, capsule |
| carbamide peroxide | Otic | Ear wax removal agent | ear drops, oral liquid |
| carboxymethylcellulose | Ophthalmic | Lubricating agent | eye drops |
| carvedilol | Cardiovascular | Beta-blocker | capsule, tablet |
| cefdinir | Anti-infective | Cephalosporin antibiotic | capsule, oral liquid |
| cefixime | Anti-infective | Cephalosporin antibiotic | capsule, tablet, oral liquid |
| ceftriaxone | Anti-infective | Cephalosporin antibiotic | injection |
| celecoxib | Analgesic | COX-II Inhibitor Non-steroidal anti-inflammatory drug | capsule, oral liquid |
| cephalexin | Anti-infective | Cephalosporin antibiotic | capsule, tablet, oral liquid |
| cetirizine | Respiratory | Antihistamine | tablet, oral liquid |
| chlorhexidine gluconate (0.12%) | Dermatologic | Anti-infective | oral liquid |
| chlorthalidone | Cardiovascular | Thiazide-like diuretic | tablet |
| cholecalciferol (vitamin D3) | Vitamin | Vitamin | capsule, tablet, oral liquid |
| ciprofloxacin | Anti-infective | Quinolone antibiotic | tablet, ear drops, eye drops, oral liquid |
| ciprofloxacin/dexamethasone | Anti-infective/anti-inflammatory | Quinolone antibiotic/corticosteroid | ear drops |
| citalopram | Central nervous system, antidepressant | Selective serotonin reuptake inhibitor (SSRI) | capsule, tablet, oral liquid |
| clarithromycin | Anti-infective | Macrolide antibiotic | tablet, oral liquid |
| clindamycin | Anti-infective | Lincosamide antibiotic | capsule, oral liquid, topical |
| clonazepam ^{CS} | Central nervous system | Benzodiazepine | tablet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|--|---|--|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| clonidine | Cardiovascular | Centrally acting alpha 2 agonist | tablet, oral liquid, patch |
| clopidogrel | Cardiovascular | Platelet inhibitor | tablet |
| clotrimazole | Anti-infective | Azole antifungal | oral troche, topical |
| conjugated estrogens (topical only) | Dermatologic | Estrogen | topical |
| crofelemer | Gastrointestinal | Antidiarrheal | tablet |
| cyanocobalamin (vitamin B12) | Vitamin | Vitamin | tablet, oral liquid, nasal spray, injection |
| cyclobenzaprine | Central nervous system | Muscle relaxant | capsule, tablet |
| cyproheptadine | Respiratory | Antihistamine | tablet, oral liquid |
| dabigatran | Blood formation and coagulation | Anticoagulant | capsule, oral granules |
| dapagliflozin | Antidiabetic | Sodium-glucose co-transporter 2 (SGLT2) inhibitor | tablet |
| dapagliflozin/metformin | Antidiabetic | SGLT2 inhibitor/biguanide | tablet |
| dapsone | Anti-infective | Sulfone antibiotic | tablet, topical |
| dexamethasone/neomycin/polymyxin b | Ophthalmic | Corticosteroid/antibacterial | eye drops, eye ointment |
| dextromethorphan/promethazine | Respiratory | Antitussive/antihistamine | oral liquid |
| diazepamCS | Central nervous system | Benzodiazepine | tablet, oral liquid, nasal spray, rectal gel |
| diclofenac | Analgesic | Non-steroidal anti-inflammatory drug | capsule, tablet, eye drops, topical |
| dicyclomine | Gastrointestinal | Antispasmodic | capsule, tablet, oral liquid |
| digoxin | Cardiovascular | Cardiac glycoside | tablet, oral liquid |
| diltiazem | Cardiovascular | Calcium channel blocker | capsule, tablet |
| diphenhydramine | Respiratory | Antihistamine | capsule, tablet, oral liquid, topical |
| diphenoxylate/atropineCS | Gastrointestinal | Antidiarrheal | tablet, oral liquid |
| disulfiram | Substance abuse | Alcohol deterrent | tablet |
| divalproex | Central nervous system | Anticonvulsant, mood stabilizer | capsule, tablet, oral liquid |
| docusate sodium | Gastrointestinal | Laxative, stool softener | capsule, tablet, oral liquid |
| donepezil | Central nervous system | Cholinesterase inhibitor | tablet, patch |
| dorzolamide | Antiglaucoma | Carbonic anhydrase inhibitor | eye drops |
| dorzolamide/ timolol | Antiglaucoma | Carbonic anhydrase inhibitor, beta-blocker | eye drops |
| doxazosin | Cardiovascular | Alpha-blocker | tablet |
| doxepin | Central nervous system | Tricyclic antidepressant (TCA) | capsule, tablet, oral solution, topical |
| doxycycline | Anti-infective | Tetracycline antibiotic | capsule, tablet, oral liquid |
| doxylamine/pyridoxine | Gastrointestinal | Anti-nausea agent | tablet |
| dronabinolCS | Gastrointestinal, appetite stimulant | Cannabinoid | capsule, oral liquid |
| dulaglutide | Antidiabetic | Glucagon-like peptide-1 receptor agonist (GLP-1 RA) | injection |
| duloxetine | Central nervous system, antidepressant | Serotonin-norepinephrine reuptake inhibitor | capsule |
| elbasvir/grazoprevir | Anti-infective | Hepatitis C antiviral | tablet |
| empagliflozin | Antidiabetic | Sodium-glucose co-transporter 2 (SGLT2) inhibitor | tablet |
| empagliflozin/metformin | Antidiabetic | SGLT2 inhibitor/biguanide | tablet |
| enalapril | Cardiovascular | Angiotensin converting enzyme (ACE) inhibitor | tablet, oral liquid |
| enalapril/hydrochlorothiazide | Cardiovascular | ACE inhibitor/ thiazide diuretic | tablet |
| entecavir | Anti-infective | Hepatitis B antiviral | tablet, oral liquid |
| epoetin alfa | Blood formation and coagulation | Erythropoiesis stimulating agent | injection |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|--|---|------------------------------|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| ergocalciferol (vitamin D2) | Vitamin | Vitamin | capsule, tablet, oral liquid |
| escitalopram | Central nervous system, antidepressant | Selective serotonin reuptake inhibitor (SSRI) | tablet, oral liquid |
| esomeprazole | Gastrointestinal | Proton pump inhibitor | capsule, tablet, oral powder |
| estradiol | Endocrine | Estrogen | tablet, topical, injection |
| ethambutol | Anti-infective | Antimycobacterial | tablet |
| ethinyl estradiol/desogestrel | Endocrine | Estrogen/Progestin | tablet |
| ethinyl estradiol/etonogestrel | Endocrine | Estrogen/Progestin | vaginal ring |
| ethinyl estradiol/levonorgestrel | Endocrine | Estrogen/progestin | tablet, patch |
| ethinyl estradiol/norethindrone | Endocrine | Estrogen/progestin | tablet |
| ethinyl estradiol/norethindrone/ferrous fumarate | Endocrine | Estrogen/progestin/iron | tablet |
| ethinyl estradiol/norgestimate | Endocrine | Estrogen/progestin | tablet |
| ethinyl estradiol/norgestrel | Endocrine | Estrogen/progestin | tablet |
| evolocumab | Cardiovascular, antihyperlipidemic | PCSK9 inhibitor | injection |
| ezetimibe | Cardiovascular, antihyperlipidemic | Cholesterol absorption inhibitor | tablet |
| ezetimibe/rosuvastatin | Cardiovascular, antihyperlipidemic | Cholinesterase inhibitor/HMG CoA reductase inhibitor | tablet |
| famciclovir | Anti-infective | Antiviral | tablet |
| famotidine | Gastrointestinal, acid reducing | Histamine 2 receptor blocker | tablet, oral powder |
| fenofibrate | Cardiovascular, antihyperlipidemic | Fibric acid derivative | capsule, tablet |
| ferrous sulfate | Vitamin | Vitamin | tablet, oral liquid |
| fexofenadine | Respiratory | Antihistamine | tablet, oral liquid |
| fidaxomicin | Anti-infective | Macrolide antibiotic | tablet, oral powder |
| filgrastim | Blood formation and coagulation | Granulocyte stimulating agent | injection |
| finasteride | Genitourinary | 5-Alpha Reductase Inhibitor | tablet |
| fluconazole | Anti-infective | Azole antifungal | tablet, oral liquid |
| flunisolide (nasal spray) | Respiratory | Corticosteroid, nasal | nasal spray |
| fluoxetine | Central nervous system, antidepressant | Selective serotonin reuptake inhibitor (SSRI) | capsule, tablet, oral liquid |
| fluoxetine/olanzapine | Central nervous system | SSRI/atypical antipsychotic, antimanic | capsule |
| fluticasone | Respiratory | Corticosteroid | inhaler, nasal spray |
| fluticasone furoate/umeclidinium/vilanterol | Respiratory | Corticosteroid/long-acting muscarinic antagonist/long-acting Beta-2 agonist | inhaler |
| fluticasone/salmeterol | Respiratory | Corticosteroid + Long acting Beta-2 Agonist, oral inhaled | inhaler |
| fluticasone/vilanterol | Respiratory | Corticosteroid/long-acting Beta-2 agonist | inhaler |
| folic acid | Vitamin | Vitamin | capsule, tablet |
| formoterol | Respiratory | Long-acting Beta-2 agonist | inhaler, nebulizer solution |
| frovatriptan | Central nervous system | Antimigraine | tablet |
| furosemide | Cardiovascular | Loop diuretic | tablet, oral liquid |
| gabapentin | Central nervous system | Anticonvulsant, mood stabilizer | capsule, tablet |
| gemfibrozil | Cardiovascular, antihyperlipidemic | Fibric acid derivative | tablet |
| glecaprevir/pibrentasvir | Anti-infective | Hepatitis C antiviral | tablet, oral pellet packet |
| glimepiride | Antidiabetic | Sulfonylurea | tablet |
| glipizide | Antidiabetic | Sulfonylurea | tablet |
| glipizide/metformin | Antidiabetic | Sulfonylurea/biguanide | tablet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|----------------------------------|---|------------------------------|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| glyburide | Antidiabetic | Sulfonylurea | tablet |
| glyburide/metformin | Antidiabetic | Sulfonylureas/Biguanides | tablet |
| glycopyrrolate | Respiratory | Anticholinergic | tablet, oral liquid |
| hepatitis A adult vaccine | Vaccines | Viral vaccine | injection |
| hepatitis A/B vaccine | Vaccines | Viral vaccine | injection |
| hepatitis B adult vaccine | Vaccines | Viral vaccine | injection |
| hepatitis B vaccine (recombinant, adjuvanted) | Vaccines | Viral vaccine | injection |
| human papilloma virus vaccine (recombinant) | Vaccines | Viral vaccine | injection |
| hydralazine | Cardiovascular | Vasodilating agents | tablet |
| hydrochlorothiazide | Cardiovascular | Thiazide diuretic | capsule, tablet |
| hydrocortisone | Anti-inflammatory | Corticosteroid | topical, tablet, enema |
| hydrocortisone/neomycin/polymyxin b | Anti-inflammatory/anti-infective | Corticosteroid/antibacterial | ear drops |
| hydrocortisone/pramoxine | Anti-inflammatory/anesthetic | Corticosteroid/anesthetic | topical |
| hydroxyzine | Respiratory or CNS | Antihistamine or anxiolytic | capsule, tablet, oral liquid |
| hyoscyamine | Gastrointestinal | Antispasmodic | tablet oral liquid |
| ibuprofen | Analgesic | Nonsteroidal anti-inflammatory drug | capsule, tablet, oral liquid |
| imiquimod | Dermatologic | Immune response modifier | topical |
| influenza vaccine (including high dose) | Vaccines | Viral vaccine | injection |
| inhaler spacer (one time only) | Respiratory | Inhaler spacer device | spacer device |
| insulin aspart | Antidiabetic | Insulin-rapid acting | injection |
| insulin degludec | Antidiabetic | Insulin | injection |
| insulin detemir | Antidiabetic | Insulin intermediate to long acting | injection |
| insulin glargine | Antidiabetic | Insulin-long acting | injection |
| insulin isophane (NPH) | Antidiabetic | Insulin-intermediate acting | injection |
| insulin lispro | Antidiabetic | Insulin-rapid acting | injection |
| insulin NPH and insulin regular | Antidiabetic | Insulin-70/30 | injection |
| insulin regular | Antidiabetic | Insulin-short acting | injection |
| ipratropium | Respiratory | Anticholinergic | inhaler, nebulizer solution |
| irbesartan | Cardiovascular | Angiotensin II receptor blocker (ARB) | tablet |
| irbesartan/hydrochlorothiazide | Cardiovascular | ARB/ thiazide diuretic | tablet |
| isoniazid | Anti-infective | Antimycobacterial | tablet, oral liquid |
| isosorbide dinitrate | Cardiovascular | Vasodilating agents | tablet |
| isosorbide mononitrate | Cardiovascular | Vasodilating agents | tablet |
| itraconazole | Anti-infective | Azole antifungal | capsule, oral liquid |
| ivabradine | Cardiovascular | Hyperpolarization-activated cyclic nucleotide-gated channel blocker | tablet, oral liquid |
| ketoconazole | Anti-infective | Azole antifungal | tablet, topical |
| labetalol | Cardiovascular | Beta-blocker | tablet |
| lactulose | Gastrointestinal | Laxative, osmotic | oral liquid |
| lamotrigine | Central nervous system | Anticonvulsant, mood stabilizer | tablet, oral liquid |
| lanolin alcohol-mo-w.pet-ceres (Eucerin) | Emmolient | Moisturizer | topical |
| lansoprazole | Gastrointestinal | Proton pump inhibitor | capsule, tablet |
| lanthanum carbonate | Gastrointestinal | Phosphate binder | tablet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|--------------------------------------|---|--|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| latanoprost | Antiglaucoma | Prostaglandin | eye drops |
| ledipasvir/sofosbuvir | Anti-infective | Hepatitis C antiviral | tablets, oral pellet packet |
| leucovorin | Vitamin | Vitamin | tablet |
| levetiracetam | Central nervous system | Anticonvulsant, mood stabilizer | tablet, oral liquid |
| levofloxacin | Anti-infective | Quinolone antibiotic | tablet, oral liquid |
| levonorgestrel | Endocrine | Progestin | tablet, intrauterine device |
| levothyroxine | Endocrine | Thyroid supplement | tablet |
| lidocaine | Anesthetic | Anesthetic | topical |
| linaclotide | Gastrointestinal | Irritable bowel syndrome agent | capsule |
| liothyronine | Endocrine | Thyroid supplement | tablet |
| liraglutide | Antidiabetic | Glucagon-like peptide-1 receptor agonist (GLP-1 RA) | injection |
| lisinopril | Cardiovascular | Angiotensin converting enzyme (ACE) inhibitor | tablet |
| lisinopril/hydrochlorothiazide | Cardiovascular | Angiotensin converting enzyme (ACE) inhibitor/ thiazide | tablet |
| lithium carbonate | Central nervous system | Mood stabilizer | capsule, tablet |
| loperamide | Gastrointestinal, antidiarrheal | Antidiarrheal | capsule, tablet, oral liquid |
| loratadine | Respiratory | Antihistamine | capsule, tablet, oral liquid |
| lorazepam ^{CS} | Central nervous system | Benzodiazepine | tablet, oral liquid |
| losartan | Cardiovascular | Angiotensin II receptor blocker (ARB) | tablet |
| losartan/hydrochlorothiazide | Cardiovascular | ARB/ thiazide diuretic | tablet |
| loteprednol etabonate | Ophthalmic | Corticosteroid | eye drops, eye gel |
| lurasidone | Central nervous system | Antipsychotic, atypical | tablet |
| magnesium oxide | Vitamin | Vitamin | capsule tablet |
| measles, mumps, rubella vaccine | Vaccines | Viral vaccine | injection |
| meclizine | Central nervous system | Antivertigo, antiemetic | tablet |
| medroxyprogesterone | Endocrine | Progestin | tablet, injection |
| megestrol | Gastrointestinal, appetite stimulant | Endocrine, progestin | tablet, oral liquid |
| meloxicam | Analgesic | Non-steroidal anti-inflammatory drug | capsule, tablet |
| meningococcal conjugate vaccine | Vaccines | Bacterial vaccine | injection |
| mesalamine | Gastrointestinal | 5-Aminosalicylate | capsule, tablet, enema, rectal suppository |
| metformin | Antidiabetic | Biguanide | tablet |
| metformin/sitagliptin | Antidiabetic | Biguanide/DPP-4 inhibitor | tablet |
| methylcellulose | Gastrointestinal | Laxative, bulk-forming | oral powder, tablet |
| methylprednisolone | Endocrine | Glucocorticoid | tablet |
| metoclopramide | Gastrointestinal | Antiemetic, prokinetic | tablet, oral liquid, nasal sprayp |
| metoprolol succinate | Cardiovascular | Beta-blocker | capsule, tablet |
| metoprolol tartrate | Cardiovascular | Beta-blocker | tablet |
| metoprolol tartrate/hydrochlorothiazide | Cardiovascular | Beta-blocker/thiazide diuretic | tablet |
| metronidazole | Anti-infective | Amebicide, trichomonaside | capsule, tablet, topical |
| midodrine | Cardiovascular | Vasopressor | tablet |
| mirtazapine | Central nervous system | Tetracyclic antidepressant | tablet |
| modafinilcs | Central nervous system | Stimulant | tablet |
| mometasone | Respiratory or Dermatologic | Corticosteroid | inhaler, nasal spray, topical |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|--|---|---|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| mometasone/formoterol | Respiratory | Corticosteroid/long-acting Beta-2 agonist | inhaler |
| mometasone/olopatadine | Respiratory | Corticosteroid/antihistamine | nasal spray |
| montelukast | Respiratory | Leukotriene receptor antagonist | tablet, oral granules |
| moxifloxacin | Anti-infective | Quinolone antibiotic | tablet, eye drops |
| multivitamin | Vitamin | Vitamin | tablet |
| multivitamin prenatal | Vitamin | Vitamin | tablet |
| multivitamin with minerals | Vitamin | Vitamin | tablet |
| mupirocin | Dermatologic | Antibiotic | topical |
| naloxone | Substance abuse | Opiate antagonist | nasal spray, injection |
| naltrexone | Substance abuse | Opiate antagonist | capsule, tablet, injection |
| naltrexone ER/bupropion ER | Anti-obesity | Anoretic agents | tablet |
| naproxen | Analgesic | Nonsteroidal anti-inflammatory drug | tablet, oral liquid |
| naratriptan | Central nervous system | Antimigraine | tablet |
| nepafenac | Anti-inflammatory | Non-steroidal anti-inflammatory drug | eye drops |
| niacin | Cardiovascular, antihyperlipidemic | Vitamin, lipotropic | capsule, tablet |
| nicotine | Substance abuse | Nicotine replacement | gum, inhaler, lozenge, nasal spray, patch |
| nifedipine | Cardiovascular | Calcium channel blocker | capsule, tablet |
| nitrofurantoin | Anti-infective | Nitrofu an derivative | capsule, oral liquid |
| nitroglycerin | Cardiovascular | Vasodilating agents | capsule, nasal spray, tablet, topical |
| norethindrone | Endocrine | Progestin | tablet |
| nortriptyline | Central nervous system, antidepressant | Tricyclic antidepressant (TCA) | capsule, oral liquid |
| nystatin | Anti-infective | Antifungal | tablet, oral liquid, topical |
| olanzapine | Central nervous system | Antipsychotic, antimanic | tablet, injection |
| olmesartan | Cardiovascular | Angiotensin II receptor blocker | tablet |
| olmesartan/hydrochlorothiazide | Cardiovascular | ARB/ thiazide diuretic | tablet |
| olopatadine | Respiratory | Anti-histamine | eye drops, nasal spray |
| omega 3 (icosapent ethyl) | Cardiovascular, antihyperlipidemic | Lipotropic | capsule |
| omega-3-acid ethyl esters | Cardiovascular, antihyperlipidemic | Lipotropic | capsule |
| omeprazole | Gastrointestinal, acid reducing | Proton pump inhibitor | capsule, tablet, oral liquid |
| ondansetron | Central nervous system | Anti-nausea | tablet, oral film |
| orlistat | Anti-obesity | Gastrointestinal lipase inhibitor | capsule |
| oseltamivir | Anti-infective | Anti-influenza antiviral | capsule, oral liquid |
| oxybutynin | Genitourinary | Bladder antispasmodic | tablet, oral liquid, topical |
| oxycodone ^{CS} | Analgesic | Opiate | capsule, tablet, oral liquid |
| pancrelipase (amylase, lipase, protease) | Gastrointestinal | Pancreatic enzyme replacement | capsule, tablet |
| pantoprazole | Gastrointestinal, acid reducing | Proton pump inhibitor | tablet, oral granules, oral liquid |
| paromomycin | Anti-infective | Amebicide | capsule |
| paroxetine | Central nervous system, antidepressant | Selective serotonin reuptake inhibitor (SSRI) | capsule, tablet, oral liquid |
| penicillin | Anti-infective | Beta-lactam antibiotic | tablet, oral liquid, injection |
| permethrin | Dermatologic | Anti-infective, scabicide | topical |
| pioglitazone | Antidiabetic | Thiazolidinedione (glitazone) | tablet |
| pitavastatin | Cardiovascular, antihyperlipidemic | HMG-CoA reductase inhibitor | tablet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|------------------------------------|---|---|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| pneumococcal 15-valent conjugate vaccine | Vaccines | Bacterial vaccine | injection |
| pneumococcal 20-valent conjugate vaccine | Vaccines | Bacterial vaccine | injection |
| pneumococcal 23-polyvalent vaccine | Vaccines | Bacterial vaccine | injection |
| podofilox | Dermatologic | Antiviral | topical |
| polycarbophil | Gastrointestinal | Laxative, bulk-forming | tablet |
| polyethylene glycol and electrolytes | Gastrointestinal | Osmotic laxative | oral liquid |
| polyethylene glycol/propylene glycol | Ophthalmic | Lubricating agent | eye drops |
| polysaccharide-iron complex | Vitamin | Vitamin | capsule |
| potassium chloride | Cardiovascular | Electrolyte replacement | capsule, tablet, oral liquid |
| prasugrel | Cardiovascular | Platelet inhibitor | tablet |
| pravastatin | Cardiovascular, antihyperlipidemic | HMG-CoA reductase inhibitor | tablet |
| prazosin | Cardiovascular | Anti-hypertensive, Alpha-blocker | capsule |
| prednisolone | Endocrine | Corticosteroid | tablet, oral liquid, eye drops |
| prednisone | Endocrine | Corticosteroid | tablet, oral liquid |
| pregabalin ^{CS} | Central nervous system | Anticonvulsant, mood stabilizer | capsule, tablet, oral liquid |
| primaquine | Anti-infective | Antimalarial | tablet |
| promethazine | Gastrointestinal | Antihistamine, antiemetic | tablet, oral liquid, rectal suppository |
| propranolol | Cardiovascular | Beta-blocker | tablet, capsule, oral liquid |
| psyllium | Gastrointestinal | Laxative, bulk-forming | capsule, oral powder |
| pyrazinamide | Anti-infective | Antimycobacterial | tablet |
| pyridoxine (vitamin B6) | Vitamin | Vitamin | capsule, tablet, oral liquid |
| pyrimethamine | Anti-infective | Antimalarial | tablet |
| quetiapine | Central nervous system | Antipsychotic, antimanic | tablet |
| respiratory syncytial virus (RSV) vaccine | Vaccines | Viral vaccine | injection |
| respiratory syncytial virus (RSV) vaccine, adjuvanted | Vaccines | Viral vaccine | injection |
| ribavirin | Anti-infective | Hepatitis C antiviral | capsule, tablet |
| rifabutin | Anti-infective | Antimycobacterial | capsule |
| rifampin | Anti-infective | Antimycobacterial | capsule |
| rifapentine | Anti-infective | Antimycobacterial | tablet |
| rifaximin | Gastrointestinal | Anti-infective | tablet |
| risperidone | Central nervous system | Antipsychotic, atypical | tablet, oral liquid, injection |
| rivaroxaban | Blood formation and coagulation | Anticoagulant | tablet, oral liquid |
| rizatriptan | Central nervous system | Antimigraine | tablet |
| rosuvastatin | Cardiovascular, antihyperlipidemic | HMG-CoA reductase inhibitor | capsule, tablet |
| sacubitril/valsartan | Cardiovascular | Neprilysin inhibitor/ARB | tablet |
| SARS-CoV-2 (COVID 19) vaccine | Vaccines | Viral vaccine | injection |
| semaglutide | Antidiabetic | Glucagon-like peptide-1 receptor agonist (GLP-1 RA) | tablet, injection |
| sertraline | Central nervous system | Selective serotonin reuptake inhibitor (SSRI) | capsule, tablet, oral liquid |
| sildenafil | Genitourinary | Phosphodiesterase type 5 inhibitor | tablet, oral liquid |
| sitagliptin | Antidiabetic | Dipeptidyl Peptidase-4 Inhibitor (DPP-4 inhibitor) | tablet |
| smallpox/monkeypox vaccine | Vaccines | Viral vaccine | injection |
| sofosbuvir/velpatasvir | Anti-infective | Hepatitis C antiviral | tablet, oral pellet packet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|--|--|---|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| sofosbuvir/velpatasvir/voxilaprevir | Anti-infective | Hepatitis C antiviral | tablet |
| spironolactone | Cardiovascular | Potassium sparing diuretic | tablet, oral liquid |
| spironolactone/hydrochlorothiazide | Cardiovascular | Potassium sparing diuretic combinations | tablet |
| sucralfate | Gastrointestinal | Gastric acid buffer | tablet, oral liquid, mucosal paste |
| sulfadiazine | Anti-infective | Sulfonamide antibiotic | tablet |
| sulfamethoxazole/trimethoprim | Anti-infective | Sulfonamide antibiotic | tablet, oral liquid |
| sumatriptan | Central nervous system | Antimigraine | tablet, injection, nasal spray |
| tadalafil | Genitourinary | Phosphodiesterase type 5 inhibitor | tablet, oral liquid |
| tamsulosin | Genitourinary | Alpha-blocker | capsule |
| terazosin | Cardiovascular | Alpha-blocker | capsule |
| terconazole | Anti-infective | Azole antifungal | topical, vaginal suppository |
| testosterone ^{CS} | Endocrine | Androgen | injection, gel, patch (<i>note: testosterone undecanoate is nonformulary</i>) |
| tetanus diphtheria (Td) vaccine | Vaccines | Bacterial vaccine | injection |
| tetanus diphtheria-acellular pertussis (Tdap) vaccine | Vaccines | Bacterial vaccine | injection |
| timolol | Antiglaucoma | Beta blocker | eye drops, tablet |
| tinidazole | Anti-infective | Amebicide, trichomonoaside | tablet |
| tiotropium | Respiratory | Anti-cholinergic, oral inhaled | inhaler |
| tiotropium/olodaterol | Respiratory | Long-acting muscarinic antagonist/long-acting Beta-2 agonist | inhaler |
| tizanidine | Central nervous system | Muscle relaxant | capsule, tablet |
| topiramate | Central nervous system | Anticonvulsant | capsule, tablet, oral liquid |
| tramadol ^{CS} | Analgesic | Opioid | capsule, tablet, oral liquid |
| travoprost | Antiglaucoma | Prostaglandin | eye drops |
| trazodone | Central nervous system, antidepressant | Serotonin reuptake inhibitor | tablet |
| tretinoin | Dermatologic | Anti-acne retinoid | capsule, topical |
| triamcinolone | Respiratory or Dermatologic | Corticosteroid | nasal spray, topical, oral paste |
| triamcinolone/nystatin | Dermatologic | Corticosteroid/antifungal | topical |
| triamterene/hydrochlorothiazide | Cardiovascular | Potassium sparing/thiazide diuretic | capsule |
| umeclidinium | Respiratory | Anticholinergic | inhaler |
| umeclidinium/vilanterol | Respiratory | Anticholinergic/long-acting Beta-2 agonist | inhaler |
| valacyclovir | Anti-infective | Antiherpetic antiviral | tablet |
| valganciclovir | Anti-infective | Antiherpetic antiviral (CMV) | tablet |
| valproic acid | Central nervous system | Anticonvulsant, mood stabilizer | capsule, oral liquid |
| valsartan | Cardiovascular | Angiotensin II receptor blocker (ARB) | tablet, oral liquid |
| valsartan/hydrochlorothiazide | Cardiovascular | ARB/ thiazide diuretic | tablet |
| vancomycin | Anti-infective | Glycopeptide antibiotic | capsule, oral liquid |
| ildenafil | Genitourinary | Phosphodiesterase type 5 inhibitor | tablet |
| varenicline | Smoking cessation | Partial nicotine agonist | tablet, nasal spray |
| venlafaxine | Central nervous system, antidepressant | Serotonin-norepinephrine reuptake inhibitor | capsule, tablet |
| verapamil | Cardiovascular | Calcium channel blocker | capsule, tablet |
| vitamin B complex | Vitamin | Vitamin | capsule, tablet |
| vitamin C | Vitamin | Vitamin | tablet |

| Florida AIDS Drug Assistance Program (ADAP) Formulary September 2024 | | | |
|--|---------------------------------|------------------------------|---------------------|
| ****Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability.**** | | | |
| CS indicates controlled substance. PA indicates prior authorization required. | | | |
| Generic Name | Therapeutic Classification | Pharmacologic Classification | Dosage Forms |
| voriconazole | Anti-infective | Azole antifungal | tablet, oral liquid |
| warfarin | Blood formation and coagulation | Vitamin K antagonist | tablet |
| ziprasidone | Central nervous system | Antipsychotic, atypical | capsule, injection |
| zolpidem ^{CS} | Central nervous system | Sedative-hypnotic | capsule, tablet |
| zoster vaccine (recombinant) | Vaccines | Viral vaccine | injection |